OBI's GlycOBI has attracted an international collaborator, TegMine Therapeutics, for the co-development of novel Antibody-Drug Conjugates

Date of occurrence of the event:2025/06/06 Company name: OBI Pharma, Inc. Relationship to the Company (please enter ”head office” or ”subsidiaries”):head office Reciprocal shareholding ratios: NA Cause of occurrence: (1)OBI will be collaborating with TegMine Therapeutics, a US Biopharma pioneering the development of antibody-based therapies that target cancer-specific glycoprotein for cancer, on the generation of […]